Skip to content

Intestinal Transport of Microbial Metabolites in Chronic Kidney Disease

The Influence of Chronic Kidney Disease on Intestinal Transport of Gut Microbial Metabolites

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01752738
Enrollment
20
Registered
2012-12-19
Start date
2013-12-31
Completion date
2025-12-31
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Brief summary

Chronic kidney disease is associated with the accumulation of various metabolites, i.e., uremic retention solutes. Evidence is mounting that the colonic microbiome contributes substantially to these uremic retention solutes. Indoxyl sulfate and p-cresyl sulfate are among the most extensively studied gut microbial metabolites, and are associated with cardiovascular disease, chronic kidney disease progression and overall mortality. Mechanisms governing their intestinal uptake and metabolism, however, are currently unknown. The investigators aim to explore these transport characteristics in depth. Therefore, colonic biopsies will be sampled of patients with chronic kidney disease, analyzed and compared to available data of healthy controls. Insights in the mechanisms controlling intestinal transport and metabolism of indoxyl sulfate and p-cresyl sulfate is certainly relevant as it might lead to novel therapeutic targets in the treatment of chronic kidney disease.

Interventions

None listed

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 and ≤ 85 years * Chronic kidney disease ≤ stage III (KDOQI), i.e., estimated glomerular filtration rate (MDRD) \< 60 ml/min/m² or need of dialysis therapy 27 * Scheduled colonoscopy for diagnostic purposes * Written informed consent

Exclusion criteria

* History of gastro-intestinal disease (e.g., inflammatory bowel disease) * History of colon surgery * Recipient of a renal or other solid organ transplant * Exposure to antibiotics or drug therapy with a known influence on intestinal transporters (e.g., P-gp) or enzymes during 2 weeks before colonoscopy

Design outcomes

Primary

MeasureTime frameDescription
Percentage change in number of intestinal drug transporters and enzymes4 yearsInfluence of chronic kidney disease on intestinal drug transporters and enzymes responsible for uptake and metabolism of microbial metabolites

Countries

Belgium

Contacts

Primary ContactSander Derjongh
sander.dejongh@kuleuven.be+ 32 16 342352
Backup ContactBjorn Meijers, MD, PhD
bjorn.meijers@uzleuven.be+32 16 344 580

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026